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When allogeneic P815 mastocytoma cells (derived from DBA/2 mice) are injected 
into the anterior chamber of the eyes of BALB/c mice, they take advantage of the 
immunologic privilege within this site (1). The tumor cells proliferate relentlessly until 
the  injected  eye is  destroyed  and/or  the  tumor invades the cranial  vault  by direct 
extension and kills the host. We have reported previously that the intracameral (IC) 1 
success of P815  is accompanied by a  profound  alteration  in the capacity of tumor- 
bearing  BALB/c  mice  to  respond  to  minor  histocompatibility  antigens  of DBA/2 
tissues. BALB/c mice with progressively growing intraocular P815 tumors are unable 
to reject orthotopically grafted DBA/2 skin, although the animals retain the capacity 
to reject third party C57BL/6 skin grafts (2). The alteration in immune responsiveness 
in  these  animals resembled F1  lymphocyte-induced immune deviation  described  in 
rats by Kaplan and Streilein  (3).  To identify the unique systemic immune responses 
of animals bearing allogeneic tissues in their anterior chambers we propose the generic 
term, anterior chamber-associated immune deviation (ACAID). 
We  have  described  three  separate  manifestations  of ACAID  in  BALB/c  mice 
inoculated  IC  with  P815  cells:  (a)  progressive  growth  of  the  tumor  locally;  (b) 
transient,  significant  growth of tumors at subcutaneous  (SC)  sites where P815  cells 
have also  been  injected;  and  (c)  prolonged  (and  usually  indefinite)  acceptance  of 
DBA/2 skin grafts placed on their thoracic cages. Our previous studies of the ACAID 
phenomenon  in rats produced evidence that alloantigens presented  via the anterior 
chamber evoke both destructive and protective host immune responses (4).  The data 
further suggested that regulation of the relative participation of protective/destructive 
host  forces was focused within  the  intact  spleen  (5).  In this  paper, we describe  the 
results of experiments designed to examine a  putative splenic role in ACAID as it is 
elicited in BALB/c mice by the IC inoculation of P815 mastocytoma cells. 
Materials and Methods 
Experimental Animals.  Adult female BALB/c (H-2  a) and DBA/2 (H-2  a) mice were purchased 
from The Jackson Laboratory, Bar Harbor, Maine, and used as experimental subjects between 
3 and 5 mo of age. 
Tumor Cells.  P815 mastocytoma (DBA/2; H-2  a) cells were cultivated in suspension cultures 
in  Falcon  75-cm  2 tissue  culture  flasks  (Falcon  Labware,  Div.  of Becton,  Dickinson  & Co., 
* Supported in part by grant EY 01330 from the U. S. Public Health Service, and a grant from the 
National Society to Prevent Blindness. 
1  Abbrevzations used in thts paper: ACAID, anterior chamber-associated  immune deviation; HBSS, Hanks' 
balanced salt solution; IC, intracameral; SC, subcutaneous. 
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Oxnard, Calif.) using Dulbecco's modified Eagle's minimal essential medium supplemented 
with  10%  heat-inactivated fetal  calf serum and  gentamycin (0.05  mg/ml; Schering Corp., 
Kenilw9rth, N. J.).  EL-4 lymphoma (G57BL/6; H-2  b)  was maintained by serial passage as 
ascites  in C57BL/6 mice. Monocellular suspensions of P815 cells and EL-4 cells were washed 
in Hanks' balanced salt solution (HBSS)  and resuspended in HBSS for SC and IC injections. 
Anterior  Chamber Injections.  A  modified  quantitative technique for  depositing a  definite 
number of tumor cells into the anterior chamber of the mouse eye has been described in detail 
elsewhere  (1). Briefly, a microglass pipette (-80 #m in diameter) was fitted into a sterile infant- 
feeding tube (5 French; Cutter Laboratories, Inc., Berkeley,  Calif.) that was mounted onto a 
sterile 0.1-ml Hamilton syringe (Hamilton Co.,  Inc., Whittier, Calif.). A Hamilton automatic 
dispensing  apparatus was fitted onto the loaded syringe and was used to dispense 5-#1 quantities 
of P815 cell suspensions into the anterior chamber of mouse eyes. 
SC Injections.  1 ×  105 tumor (P815 or EL-4) cells suspended in 0.1 ml of HBSS were injected 
SC into the right rear flanks at various times relative to anterior chamber injections, as described 
in Results. 
Skin  Grafting.  Full thickness skin grafts were prepared as described elsewhere  (6). Grafts 
were  applied orthotopieally and held  in place  with  plaster of Paris bandages. Casts  were 
removed 8 d later and the grafts were inspected daily for evidence of rejection. Destruction was 
judged complete when all remnants of surface epidermis were gone. Median survival times 
were calculated where appropriate. 
Splenectomy.  Mice were anesthetized with 0.6 mg ofketamine hydrochloride (Vetalar; Parke, 
Davis & Go., Detroit, Mich.) given intramuscularly. Through a left lateral body wall incision 
the  spleen was  exteriorized  and the  splenic pedicle was  severed.  Trivial local  hemorrhage 
required no ligation of the splenic blood vessels. Control animals were similarly treated but the 
spleen and the splenic pedicle were left intact (sham splenectomy). 
Splenic  Reconstitution  with  Spleen Fragments.  Mice  were  splenectomized  and  immediately 
reconstituted with fragments of autochthonous spleens.  Briefly, after splenectomy, each whole 
spleen was aseptically sliced into either 4  (large)  or  16  (tiny) pieces.  These fragments were 
immediately re-implanted into the peritoneal cavity of the original donor. Peritoneal and skin 
incisions were closed with 5-0 chromic catgut and metal wound clips. 
Splenic Reconstitution with Spleen Cell Suspensions.  Mice were splenectomized and reconstituted 
with autochthonous,  monocellular  spleen suspensions. After splenectomy, spleen cell suspensions 
were prepared by pressing whole spleens through sterile 60-mesh stainless steel  screens.  The 
entire cellular contents from  each  spleen were  washed  (330 g  for  10  min) once in  HBSS, 
resuspended in 0.5 ml of HBSS, and injected intraperitoneally into the original donor. 
Observation and Recording of IC Tumor Growth.  Mice injected IC with P815 cells were observed 
daily with a  dissecting microscope (×8).  Ocular tumor growth was scored  according to the 
percent  of  the  anterior  chamber  occupied  by  mastocytoma  (1).  Eyes  were  observed  for 
pathological changes,  including glaucomatous enlargement, corneal  opacity and  abrasion, 
perforation of the capsule of the eye and invasion of the orbit by the tumor, neoangiogenesis, 
and corneal inflammation. 
Observation and Recording of SC Tumor Growth.  We have previously demonstrated that simul- 
taneous injection of P815 cells into the anterior chamber and into the SC flank of BALB/c 
mice resulted in the development of palpable SC tumors (1). We employed this phenomenon 
as an additional measure of AGAID. Panels of splenectomized and sham-operated mice were 
injected SC and IC with  105 P815 cells at different temporal intervals. Controls consisted of 
splenectomized and sham-operated mice injected IC with  10  s P8t5 cells and SG with 105 EL- 
4 cells. The injected flanks of these mice were palpated daily and the diameter of detectable SC 
tumors was measured with metric calipers. 
Results 
Effect of Splenectomy  on ACAID 
ORTHOTOPXC SKIN ORAVr SURVIVAL.  P815 cells, at a concentration of 105 cells/5/.d, 
were injected into the anterior chambers of eyes of panels of BALB/c mice that had 1060  INDUCTION OF ANTERIOR CHAMBER-ASSOCIATED  IMMUNE  DEVIATION 
been  splenectomized or sham  operated  7  d  earlier.  14  d  after  IC  injection of P815 
cells,  recipients  were  given  orthotopic  DBA/2  skin  grafts.  Plaster  dressings  were 
removed 8  d  later and the grafts were observed daily for evidence of rejection. The 
results are summarized in Table I. DBA/2 skin grafts placed on sham-splenectomized 
BALB/c  mice  bearing ocular P815  cells healed well,  and  in  most  of these  animals 
remained  in  healthy  condition  30  d  after  grafting.  In  contrast,  DBA/2  skin  grafts 
placed on BALB/c mice whose spleens had been removed  7 d  before IC inoculation 
of P815  cells were rejected acutely. No grafts survived beyond  11  d.  By comparison, 
the tempo of rejection of DBA/2  skin grafts placed on  sham-operated or splenecto- 
mized BALB/c mice that received no IC inoculation of P815  cells resembled that of 
untreated control BALB/c mice; median graft survival times of ~  13 d  were observed. 
These  data  indicate  that  an  intact  spleen  is  essential  for  ACAID  as  expressed  as 
prolonged acceptance of DBA/2 skin allografts. 
GROWTH OF SC P815 TUMORS.  P815  cells (105)  fail to grow into palpable tumors 
when  injected into the flanks of normal BALB/c mice. We have previously demon- 
strated  that  simultaneous  injection  of  P815  cells  IC  and  SC  into  the  flank  of 
BALB/c  mice  results  in  the  transient  growth  of SC  tumors,  another  expression of 
ACAID. To examine the possible participation of an intact spleen in this phenomenon, 
P815 cells (105)  were inoculated simultaneously IC and SC into BALB/c mice of the 
following panels  consisting of 8-10  animals  each:  (a)  splenectomized, or  (b)  sham 
operated 7 d before injections. Similar mice that received P815 cells IC and EL-4 cells 
SC  (EL-4  is  a  lymphoma  derived  from  C57BL/6  mice)  were  used  as controls.  SC 
tumors became palpable in the flanks Of sham-operated mice that received P815 cells 
SC.  However,  no  tumors  developed in  any of the other panels.  The  lack of tumor 
development  in  the  mice  of the  panel  that  received  P815  SC  after  splenectomy  is 
consistent  with  the  results  of  the  skin  grafting  experiments  described  above,  and 
indicates that  an  intact spleen is essential for ACAID expressed as SC  P815  tumor 
growth. The data from the recipients of EL-4 cells underscore the fact that ACAID is 
an immunologically specific state. 
GROWTH OF P815 TUMORS IN ANTERIOR CHAMBERS.  The fact that P815 cells grow 
unabatedly  in  the  anterior  chamber  of BALB/c  eyes, but  not  at  other  body sites, 
suggests that  progressive IC  tumor growth  is yet another  expression of ACAID. To 
test the role of the spleen in ACAID expressed IC, panels of BALB/c mice were sham 
TABLE  I 
Effect of Splenectomy on ACAID Induced in BALB/c Mice by IC Inoculation of PSI5 Cells 
Experimental  Pattern of DBA/2 skin graft survival, day of inspection  Graft sur- 
panels  8  9  l0  11  12  13  14  15  20  30  vival* 
SPLX  P815 IC  % 
No  No  5~:  5  5  5  5  5  2  1  0  0  0 
No  Yes  15  15  15  15  15  15  14  14  13  12  80 
Yes  No  9  9  9  9  7  7  2  1  0  0  0 
Yes  Yes  7  1  1  1  0  0  0  0  0  0  0 
Mice were splenectomized on day -7, injected IC with P815 cells on day 0, and grafted 
with DBA/2 skin on day 14. 
* Percent of grafts that survived beyond 30 d. 
:~ Data presented as number of grafts surviving on each day of inspection. j.  WAYNE  STREILEIN AND JERRY  Y.  NIEDERKORN  1061 
operated or splenectomized 7 d before IC inoculation of P815 cells. Eyes of these mice 
were examined daily with  a  dissecting microscope  (×8)  and  tumor  growth  scored 
according to the proportion (%) of the anterior chamber occupied by grossly visible 
tumor  tissue.  The  results,  shown  in  Fig.  1,  reveal  that  both  spleen-intact  and 
splenectomized mice developed ocular tumors. In spleen-intact mice, the tumors grew 
rapidly, filling the anterior chamber within  7 d  after injection.  Progressive growth 
subsequently perforated the globe by the  14th d  and invaded the orbit. In contrast, 
the pace of tumor growth in the eyes of splenectomized mice was considerably slower, 
the  anterior  chamber  not  being  filled  with  tumor  until  17  d  after  inoculation. 
Moreover,  perforation  of the  globe  and  invasion  of the  ocular  orbit  was  never 
observed. Thereafter, gradual resolution of the tumor took place without evidence of 
an  acute  inflammatory response.  Whereas  tumor cells  in  the  eyes of spleen-intact 
animals invaded the cranial vault, no such invasion was observed in splenectomized 
animals.  Instead,  all  of these  animals  survived,  although  resolution  of the  ocular 
tumor resulted  in  destruction of the eye. Thus,  ACAID,  which  permits  aggressive 
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FIG.  1.  Growth patterns of anterior chamber tumors in splenectomized (  ) and sham-splenec- 
tomized  (- -  -)  BALB/c  mice following IC inoculation of 105  P815  mastocytoma cells.  Ischemic 
necrosis, (*).  Each point represents the mean accumulation of tumor within the anterior chamber 
as assessed by visual inspection with a  dissecting microscope, e.g.,  25  =  25% of anterior chamber 
occupied by tumor mass. There were 10 mice per group. 
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Fla.  2.  Influence of P815  mastocytoma cells  inoculated SC on growth patterns of IC inoculated 
P815  cells.  BALB/c mice were either splenectomized  (  )  or sham splenectomized  (- -  -)  7 d 
before IC inoculation of 10  s P815  cells.  Label  in upper right corner of each panel represents time 
interval between SC  and  IC inoculations of P815  cells.  Minus sign indicates that  SC  inoculation 
preceded IC inoculation by (N) days. Responses that reach the baseline signify that tumor resolution 
has  taken  place.  There  were  10  animals  per  group.  Necrosis,  (*).  No  ocular  tumors developed, 
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invasion of the eye and periocular tissues by P815 tumor, is dependent upon an intact 
spleen. 
ROLE OV SPECIFIC  SENSXTIZATmN.  The next series of experiments was designed to 
determine  whether  immunization  of BALB/c mice with  DBA/2  alloantigens  could 
influence  the  growth  of P815  cells  injected  IC  into  splenectomized  recipients.  The 
experimental  protocol was:  panels of BALB/c mice were sham operated or splenec- 
tomized 7 d before IC inoculation of P815 cells. Mastocytoma cells (105) were injected 
SC  into  these  mice  2  or  4  d  before,  simultaneous  with,  or  2  or  4  d  after  the  IC 
injection.  Controls were panels  of mice that  were sham  operated  or splenectomized 
and  inoculated  IC with  P815, but  received no SC  injection of tumor cells.  Growth 
patterns  of intraocular  tumors,  evaluated  and  scored  as  previously  described,  are 
shown in Fig. 2. In general, SC injection of BALB/c mice with P815 cells is capable 
of immunizing  the  hosts,  thereby  thwarting  subsequent  growth  of the  intraocular 
neoplasms.  In spleen-intact  mice, the SC injection must precede the IC injection by 
at  least  7  d  to  achieve  this  effect.  This  requisite  interval  was  foreshortened  in 
splenectomized  mice.  SC  injection  of P815  cells  as late  as  4  d  before IC challenge, 
prevented the growth of ocular tumors in these animals.  As the interval between  SC 
and IC injections was shortened,  and especially when the  SC injection  followed the 
IC injection,  the effectiveness of the  host  anti-tumor  response became progressively 
more feeble. Not only did larger tumor masses develop IC, but intense inflammatory 
reactions were observed.  Although the host response effectively destroyed the tumor 
cells and the hosts survived, the eyes were destroyed in the process. Thus, splenectomy 
can conspire with a regimen of specific sensitization to interfere with the development 
of ACAID. However, careful timing of the two components appears to be required if 
preservation of a  functional eye is desired. 
Reconstitution  of ACAID  in  Splenectornized  Mice.  We  next  attempted  to  identify,  if 
possible,  the splenic mechanism(s)  that  is important  in the development  of ACAID. 
We first prepared single cell suspensions from normal BALB/c spleens and inoculated 
one-donor equivalents  intraperitoneally  into  recipient  BALB/c mice whose  spleens 
had  been  removed  surgically.  4  d  later,  P815  cells  were  inoculated  IC  in  these 
recipients; 2 wk later, they were grafted orthotopically with DBA/2 skin. The survival 
of these test  grafts and the growth pattern  of the intraocular  tumors were examined 
and scored daily. In companion experiments, normal BALB/c spleens were sliced into 
(a)  large  fragments,  4  per  spleen;  or  (b)  tiny  framgents,  16  per  spleen;  one  donor- 
equivalent  was placed  intraperitoneally  into freshly splenectomized  BALB/c recipi- 
TABLE II 
Restoration of ACAID in Splenectomized  BALB/c Mice Inoculated IC with P815 Cells 
Reconstitution with 
Pattern of DBA/2 skin graft survival, day of inspection 
8  9  10  11  12  13  14  15  20  30 
Fate of 
ocular tu- 
mors* 
None  7  1  l  1  0  0  0  0  0  0  7/0 
Monodisperse spleen cells  9  7  5  5  5  5  5  5  4  4  7/2 
Large spleen fragments  8  5  4  4  4  4  4  4  4  3  0/8 
Small spleen fragments  6  4  2  1  0  0  0  0  0  0  6/0 
No splenectomy  8  8  8  8  8  8  7  7  7  6  0/8 
* Ocular  tumors were either destroyed or grew progressively into enormous orbital  tumors: destroyed/ 
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TABLE III 
Effect of Timed Splenectomy on Development of ACAID in BALB/c Mice Inoculated IC with P815 
Cells 
Time of splenec-  Pattern of DBA/2 skin graft survival, day of inspection 
tomy in relation to  Graft sur- 
IC P815 inocula-  vival*  8  9  10  11  12  13  14  15  20  30  tion 
% 
7 d before  7  1  1  1  0  0  0  0  0  0  0 
4 d after  7  7  6  2  0  0  0  0  0  0  0 
6 d after  8  6  3  2  1  0  0  0  0  0  0 
8 d after  9  8:1:  8  8  8  8  8  8  5  5  55 
10 d after  6  6  6  5  5  5  5  5  5  4  67 
14 d after  10  10  10  10  10  10  10  10  10  9  90 
None  8  8  8  8  8  8  7  7  7  6  75 
* Percent of grafts that survived beyond 30 d. 
:~ All of these grafts underwent severe inflammatory crises, although most recovered. 
ents. These animals also were inoculated IC with P815 cells and subsequently grafted 
with  DBA/2 skin. The results of these experiments are presented in Table II. From 
the  standpoint  of test  skin  allografts,  ACAID  was  restored  in  almost  50%  of the 
splenectomized animals that had received monodispersed spleen cells or large splenic 
fragments:  these animals accepted DBA/2 skin grafts for more than  30 d.  However, 
recipients of spleen cell suspensions displayed patterns of ocular tumor growth more 
consistent  with  splenectomized  recipients;  their  IC  tumors  grew  modestly,  then 
resolved,  leaving behind  a  phthisic,  nonfunctional  eye.  In  contrast,  ocular  tumors 
grew  to  enormous  size  in  splenectomized  animals  reconstituted  with  large  splenic 
fragments;  this  pattern  of  growth  resembled  closely  the  growth  of  P815  cells  in 
anterior chambers of spleen-intact BALB/c mice. Necropsy of these animals 30 d  after 
grafting  with  DBA/2  skin  revealed  large  nodules  of easily identifiable and  viable 
splenic  tissue  attached  to  peritoneal  surfaces.  As  a  consequence,  these  fragments 
assumed  the  intact  spleen's role of promoting ACAID. In  contrast,  splenectomized 
recipients of tiny fragments of spleen failed to express ACAID; instead, they displayed 
ocular tumor  growth  and  graft  rejection patterns consistent with the asplenic state. 
This unexpected finding suggests that the spleen's contribution to the development of 
ACAID is complicated and may comprise several components. One component resides 
among lymphoid cells that  are dissociable from  normal spleens rendered  into single 
cell suspensions.  However,  there must  be another  component(s)  that  resides among 
nonlymphoid stromal cells and/or  a  unique  architectural quality of the spleen; it is 
this latter component(s) that allows large, but not small, splenic fragments to promote 
immune deviation in splenectomized mice who develop progressively growing intra- 
ocular P815  tumors. 
Time Course of Splenic Dependence  of ACAID.  The experiments in which P815 cells 
were injected at varying intervals into IC and SC sites suggested that development of 
ACAID is a  dynamic process. The results of the splenectomy experiments described 
thus  far merely confirm that  removal of the spleen before IC injection of P815  cells 
prevents the development of ACAID. The next experiments were designed to examine 
the temporal sequence during which the spleen exerts its putative role. Accordingly, 
panels of BALB/c  mice,  inoculated IC on  day 0  with  P815  cells, were subjected to 1064  INDUCTION  OF  ANTERIOR  CHAMBER-ASSOCIATED  IMMUNE  DEVIATION 
splenectomy at 4, 6, 8, 10, and 14 d thereafter. All mice were test-grafted orthotopically 
with  DBA/2  skin  on  day  14  and  graft  survival  was  assessed  as  a  measure  of the 
development of ACAID. The results of these experiments, summarized in Table III, 
are particularly illuminating. Whatever the role of the spleen in the development and 
expression of ACAID, it has not had sufficient time to exert its action within 4 d of IC 
injection of P815 cells. Mice splenectomized at 4 d rejected DBA/2 skin grafts acutely. 
By  14 d, however, the splenic role in ACAID appeared to be complete: 9 of 10 mice 
splenectomized at this time retained their test skin grafts indefinitely (beyond 30 d). 
In fact, the spleen had accomplished its task in some animals as early as 8 d; the effect 
was virtually complete in mice injected IC 10 d earlier with P815 cells. These results 
indicate that a specific interval (between 6 and  10 d after IC inoculation)  is required 
for an intact spleen to promote the development of ACAID. Of equal interest  is the 
realization that an intact spleen is not required thereafter for the continued expression 
of ACAID. In mice whose spleens were removed 14 d after IC injection of P815 cells, 
progressive  tumor  growth  was  observed  within  the  orbit.  The  tumor  relentlessly 
invaded the cranial vault as though the host's spleen were intact. 
Discussion 
BALB/c mice inoculated either SC or IC with allogeneic P815  mastocytoma cells 
suffer profoundly  different  consequences.  The  SC  challenge  elicits  a  vigorous host 
immune response that prevents the tumor cells from establishing a viable graft; from 
clinical  appearances, these mice are perfectly healthy.  In contrast,  the IC challenge 
represents a major threat to the health of the host. At the very least, the tumor invades 
the eye locally, causing blindness.  In most IC-injected animals, however, a  systemic 
perturbation  of the  host's immune  response occurs,  a  phenomenon  we have called 
"anterior chamber-associated immune deviation".  ACAID, which  expresses itself as 
progressive tumor growth within the eye, transient growth of SC injected P815 cells, 
and prolonged acceptance of DBA/2 skin grafts, is immunologically specific. 
The studies  reported  here  focus on  the  role of the  spleen  in  the  development  of 
ACAID.  BALB/c  mice,  otherwise  destined  to  die  from  the  effects  of tumor  cells 
growing  within  their  eyes, survive  this  challenge  if their  spleen  has  been  removed 
before IC inoculation.  Moreover, in the absence of a spleen, a specific immunization 
protocol with SC injected P815 cells can be devised that results in an immune response 
so  effective  it  destroys  the  tumor  before  the  eye's  functional  integrity  has  been 
disrupted. 
Claims  for unique  immunologic properties  of the  spleen  have been  made  many 
times  (7-9).  Recently,  with  the  advent  of the  notion  of immunoregulation  and  a 
prominent role for suppressor cells, the spleen has come to be regarded as the major, 
though  not  the  only,  site  in  which  suppressor  cells  develop,  mature,  and/or  are 
amplified.  Two  independent  laboratories  have  produced  data  consistent  with  the 
hypothesis  that  the  spleen  harbors  populations  of suppressor  cells  that  can  down- 
regulate  alloimmune responses to minor histocompatibility antigens  (10,  11). How- 
ever,  other  investigators  failed  to  find  comparable  splenic  properties  in  similar 
alloimmune  responses  (12,  13). Controversy  also  surrounds  the  spleen's  putative 
involvement  in  contact  hypersensitivity  (14)  and  tumor  immunity  (15,  16). The 
controversy stems at least in part from heterogeneity among the immune phenomena 
being studied. The dramatic and highly reproducible role identified for the spleen in j.  WAYNE  STREILEIN  AND JERRY  Y.  NIEDERKORN  1065 
ACAID  offers  an  ideal  opportunity  to  investigate  the  generation  of suppression 
mechanisms within this organ. 
Development of the  splenic-dependent  phase  of ACAID  begins  about  4  d  after 
P815 cells are inoculated IC into BALB/c mice. During the next 6  d, this phase is 
virtually completed, and ACAID becomes established as a systemic pattern of immune 
reactivity,  freed  of  its  splenic  dependence.  It  is  presumed  that  during  this  6-d 
"window", alloantigenic signals from the anterior chamber of the eye are delivered 
intravenously  to  the  spleen,  wherein  they  are  transduced  into  a  predominately 
protective rather than destructive immune response. The fact that  the spleen is no 
longer  required  for  ACAID  after  10  d  implies  that  the  protective  response  has 
disseminated systemically and is self-sustaining. We have no direct information about 
the  cellular  basis  of the  process  taking  place  within  the  spleen.  Reconstitution 
experiments with monodisperse spleen cells and with splenic fragments transplanted 
intraperitoneally into splenectomized mice only partially resolved the dilemma. The 
results suggest that although splenic cells participate in the induction of ACAID, the 
whole of the  spleen's  role must  be greater than  the sum  of its  parts.  Perhaps  this 
realization addresses unique architectural features of this organ, and/or its distinctive 
stroma  and  microenvironment.  Numerous  strategies  have  been  employed in  other 
murine systems to identify subpopulations of functionally distinct lymphocytes, and 
we intend to bring those to bear on these phenomena. However, considerable ingenuity 
will be required to analyze that component of the spleen's role in ACAID that is not 
restored solely by monodisperse spleen cells, but  requires the use of large  (but  not 
small) splenic fragments. 
In this model, the precision with which the host immune response destroys intra- 
ocular  tumors  varies  considerably.  In  the  experiments  reported  here,  splenectomy 
before IC ioculation of P815 cells equips the host with a  vigorous immune response 
that destroys the ocular tumor; but the anatomic integrity of the eye is destroyed in 
the  process.  A  much  more  precise  immune  response  is  evoked  in  splenectomized 
BALB/c mice who are immunized with P815 cells SC several days before intraocular 
challenge  with  P815  cells;  tumor  destruction  within  the  eyes of these  animals  is 
accomplished without  significant  disruption  of the  functional  integrity of the  eye. 
This  is  the  second  instance  in  which  an  elegantly  specific,  yet  highly  effective 
alloimmune response has been generated in animals with ACAID. We have recently 
found that,  if the  immunogenetic disparity between  P815  cells  (DBA/2)  and  their 
potential IC recipients involves both K and D regions of the H-2 complex, the tumor 
ceils are destroyed, whereas the eye is spared (17). Alloantigenic differences restricted 
to only one or  the  other of these  two  loci evoke an  immune  response  that  causes 
innoncent bystander ocular damage while destroying its specific tumor targets. Thus, 
we have been able to identify several important factors that  govern the precision of 
the  alloimmune  response as  it  expresses itself within  the  eye. If these experiments 
address the clinical  realm of ocular neoplasms,  then perhaps successful therapeutic 
strategies can be developed that take these factors into account. 
Summary 
Anterior chamber-associated immune deviation (ACAID) expresses itself in BALB/ 
c mice inoculated intracamerally with P815 cells in three ways: progressive growth of 
the tumor within the eye, transient growth of P815 cells injected subcutaneously, and 1066  INDUCTION OF ANTERIOR CHAMBER-ASSOCIATED  IMMUNE DEVIATION 
prolonged  acceptance  of DBA/2  skin  allografts.  The  spleen  was  found  to  play  a 
crucial role in the development of ACAID. Splenectomized animals bearing intraca- 
meral P815 tumors reject DBA/2 skin grafts in an accelerated manner. A  functioning 
spleen was required during the first  10 d  after intracameral  inoculation of P815 cells, 
but  not  thereafter.  Reconstitution  experiments  revealed  that  the  spleen's  ability  to 
support the induction of ACAID depends partly upon its constituent lymphoid cells, 
but also upon either a stromal component or a unique architectural arrangement that 
can only be restored with splenic fragments. The data hold promise that therapeutic 
protocols using appropriately  timed splenectomy and  specific immunization  can  be 
devised  to induce  hosts  bearing  intraocular  tumors  to mount  an  immune  response 
sufficiently vigorous to destroy the  tumor within  the eye, and sufficiently precise to 
preserve the functional and anatomic integrity of the eye. 
We  greatly appreciate  the  excellent  technical  assistance  of Ms.  Lanya Lonsberry  and  Ms. 
Elizabeth Mayhew. The manuscript was carefully prepared by Ms. Sara Howard and critically 
reviewed graciously by Dr. R. E. Billingham. 
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